X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (307) 307
oncology (259) 259
humans (251) 251
olaparib (239) 239
ovarian cancer (230) 230
olaparib maintenance therapy (204) 204
female (191) 191
poly polymerase (152) 152
cancer (142) 142
chemotherapy (123) 123
mutation (115) 115
ovarian neoplasms - drug therapy (110) 110
homologous recombination (98) 98
open-label (95) 95
breast cancer (92) 92
tumors (89) 89
parp inhibitor (85) 85
dna repair (84) 84
parp inhibitors (80) 80
ovarian neoplasms - genetics (77) 77
care and treatment (72) 72
antineoplastic agents - therapeutic use (67) 67
poly polymerase inhibitors - therapeutic use (67) 67
ovarian-cancer (65) 65
pharmacology & pharmacy (65) 65
maintenance therapy (64) 64
animals (63) 63
dna damage (59) 59
clinical trials (58) 58
double-blind (58) 58
deoxyribonucleic acid--dna (57) 57
brca (55) 55
breast-cancer (55) 55
fallopian-tube (55) 55
research (55) 55
middle aged (54) 54
brca1 protein - genetics (53) 53
monosaccharides (52) 52
sugars (52) 52
aged (50) 50
brca1 (50) 50
cancer therapies (50) 50
ovarian neoplasms - pathology (47) 47
phthalazines - therapeutic use (46) 46
piperazines - therapeutic use (46) 46
poly polymerase inhibitors - pharmacology (46) 46
adult (45) 45
brca2 protein - genetics (45) 45
repair (45) 45
health aspects (44) 44
endocrine system diseases (42) 42
genetic aspects (42) 42
medicine & public health (42) 42
obstetrics & gynecology (42) 42
pegylated liposomal doxorubicin (42) 42
patients (41) 41
poly polymerase inhibitors (40) 40
review (40) 40
synthetic lethality (40) 40
antineoplastic agents - pharmacology (38) 38
dna-repair (38) 38
parp (38) 38
recurrent epithelial ovarian (38) 38
therapy (38) 38
analysis (37) 37
carcinoma (36) 36
negative breast-cancer (36) 36
ribose (36) 36
dna-damage (35) 35
drug therapy (35) 35
inhibitors (35) 35
molecular targeted therapy (35) 35
mutations (35) 35
women (35) 35
bevacizumab (34) 34
brca1 protein (34) 34
carcinoma, ovarian epithelial (34) 34
cell line, tumor (34) 34
epithelial ovarian (34) 34
poly polymerases - metabolism (34) 34
brca2 (33) 33
platinum (33) 33
somatic mutations (33) 33
combination (32) 32
genes, brca1 (32) 32
male (32) 32
phase-i (32) 32
phthalazines - pharmacology (32) 32
piperazines - pharmacology (32) 32
apoptosis (30) 30
biomarkers (30) 30
brca mutation (30) 30
brca2 mutations (30) 30
medical research (30) 30
multicenter (30) 30
survival (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
hematology, oncology and palliative medicine (29) 29
germ-line mutation (28) 28
polymerase (28) 28
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Current Breast Cancer Reports, ISSN 1943-4588, 12/2010, Volume 2, Issue 4, pp. 190 - 197
Poly (ADP-ribose) polymerase (PARP) inhibitors, a novel class of drugs that target tumors with DNA repair defects, have received tremendous enthusiasm. Early... 
Hormone receptor-negative breast cancer | Internal Medicine | Oncology | BSI-201 | Poly (ADP-Ribose) Polymerase (PARP) inhibitor | Olaparib | Breast cancer | DNA repair | Triple-negative breast cancer | Prevention | BRCA | Medicine & Public Health | Surgical Oncology
Journal Article
Drugs, ISSN 0012-6667, 5/2011, Volume 71, Issue 8, pp. 947 - 967
Over the past two decades, empirical optimization of cytotoxic chemotherapy combinations and surgical debulking procedures have improved outcomes and survival... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Temsirolimus | Olaparib | Bevacizumab | Matuzumab | AP-23994 | Pertuzumab | Paclitaxel | LY-294002 | Cetuximab | Gefitinib | Batimastat | BEZ-235 | Ispinesib | Cediranib | Pazopanib | Zibotentan | Imatinib | Selumetinib | Alisertib | Perifosine | Ovarian-cancer | PD-98059 | Oregovomab | Erlotinib | XL-147 | SF-1126 | R-1549 | Tozasertib | Fosbretabulin | Letrozole | Trastuzumab | STAGE EPITHELIAL OVARIAN | PHASE-II TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | PLATINUM-RESISTANT OVARIAN | TUMOR-SUPPRESSOR GENES | AURORA-KINASE INHIBITORS | RECEPTOR MESSENGER-RNA | PRIMARY PERITONEAL CARCINOMA | PHARMACOLOGY & PHARMACY | TRAIL-INDUCED APOPTOSIS | TOXICOLOGY | MATRIX-METALLOPROTEINASE INHIBITOR | Humans | Neoplasms, Glandular and Epithelial - metabolism | Clinical Trials as Topic | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Animals | Molecular Targeted Therapy - trends | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Female | Ovarian Neoplasms - metabolism | Ovarian Neoplasms - drug therapy | Molecular Targeted Therapy - methods | Chemotherapy | Physiological aspects | Development and progression | Genetic aspects | Cellular signal transduction | Research | Drug therapy | Ovarian cancer | Cancer | Index Medicus
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 9/2012, Volume 135, Issue 2, pp. 505 - 517
Journal Article
Epigenetics, ISSN 1559-2294, 11/2012, Volume 7, Issue 11, pp. 1225 - 1229
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2012, Volume 106, Issue 3, pp. 468 - 474
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2012, Volume 30, Issue 4, pp. 1493 - 1500
Background The aim of this phase I study was to determine the safety and tolerability and to establish the maximum tolerated dose (MTD) of orally administered... 
Medicine & Public Health | Targeted agents | PARP inhibitors | Oncology | Topotecan | Olaparib | Maximum tolerated dose | Pharmacology/Toxicology | DNA repair | SENSITIVITY | INDUCTION | CANCER | MAMMARY-TUMORS | ONCOLOGY | RESISTANCE | PHARMACOLOGY & PHARMACY | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Demography | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Enzyme Inhibitors - pharmacokinetics | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Piperazines - pharmacokinetics | Enzyme Inhibitors - adverse effects | Phthalazines - administration & dosage | Topotecan - adverse effects | Treatment Outcome | Piperazines - therapeutic use | Neoplasms - diagnostic imaging | Topotecan - therapeutic use | Enzyme Inhibitors - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Neoplasms - drug therapy | Maximum Tolerated Dose | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - pharmacokinetics | Topotecan - administration & dosage | Aged | Phthalazines - adverse effects | Cohort Studies | Studies | Clinical trials | Inhibitor drugs | Drug therapy | Patients | Tumors | Index Medicus
Journal Article
ONCOLOGY (United States), ISSN 0890-9091, 04/2013, Volume 27, Issue 4, pp. 298 - 304
  Molecular targeting of recurrent high-grade serous cancers has been challenging, and genomic analyses to date have generally failed to reveal high-frequency... 
TRIAL | OLAPARIB | THERAPY | ONCOLOGY | BEVACIZUMAB | RELAPSED OVARIAN-CANCER | CARCINOMA | EPITHELIAL OVARIAN | CHEMOTHERAPY | Carcinoma, Ovarian Epithelial | Neoplasm Recurrence, Local - drug therapy | Female | Ovarian Neoplasms - drug therapy | Humans | Neoplasms, Glandular and Epithelial - drug therapy | Chemotherapy | Care and treatment | Research | Health aspects | Ovarian cancer